Skip to main content
. 2019 Aug 20;10(49):5092–5102. doi: 10.18632/oncotarget.27149

Figure 2.

Figure 2

Increased cAMP release (A) and PKA activity (B) in AML 12 cells treated with neurotensin analogue JMV. Forskolin treatment is shown in (A) as a positive control; PKA activity assays were performed with and without cAMP stimulation, with demonstration of abolishment of activity with PKI, a specific inhibitor of PKA. *denotes p < 0.05 in cells with and without JMV treatment.